DiscoveryProbe™ FDA-approved Drug Library: Redefining High-Throughput Drug Repositioning and Target Identification

Principle and Setup: The Power of a Curated FDA-Approved Bioactive Compound Library

Modern biomedical research increasingly relies on robust, mechanism-diverse compound collections to accelerate the path from bench to bedside. The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) by APExBIO is a high-throughput screening drug library encompassing 2,320 pre-dissolved compounds approved by major regulatory agencies (FDA, EMA, HMA, CFDA, PMDA) or listed in recognized pharmacopeias. Each compound—meticulously curated and supplied at 10 mM in DMSO—represents a well-characterized pharmacological agent, spanning receptor agonists/antagonists, enzyme inhibitors, ion channel modulators, and signaling pathway regulators.

This FDA-approved bioactive compound library is tailored for both high-throughput (HTS) and high-content screening (HCS) workflows. The versatile format options (96-well, deep well, or 2D barcoded tubes) ensure compatibility with automation, minimizing manual handling and maximizing reproducibility. The library's stability profile (12 months at -20°C; up to 24 months at -80°C) supports longitudinal and multi-phase screening campaigns, while the pre-dissolved format eliminates solubility variability and preparation bottlenecks.

Key Features at a Glance

• 2,320 clinically approved, bioactive compounds
• Pre-dissolved 10 mM DMSO solutions, ready for assay
• Multiple plate/tube formats for flexible experimental design
• Comprehensive coverage: oncology, neurodegeneration, infectious and rare diseases, metabolic, and more
• Quality assurance: Each compound linked to public pharmacological and regulatory data

Step-by-Step Experimental Workflow: Streamlining Drug Repositioning and Target Discovery

The DiscoveryProbe FDA-approved Drug Library is engineered to optimize every stage of drug repositioning screening and pharmacological target identification. Below is a stepwise protocol, highlighting enhancements enabled by this compound collection.

1. Pre-screening Preparation
   • Thaw pre-dissolved plates at room temperature; avoid repeated freeze-thaw cycles.
   • Plan compound transfer using automated liquid handling systems compatible with 96-well or deep-well formats.
   • Confirm compound identity and concentration via 2D barcoding and included reference documentation.
2. Assay Design and Optimization
   • Select screening modality: high-throughput (e.g., cell viability, enzymatic activity) or high-content (e.g., imaging-based phenotypic screens).
   • Determine assay window and signal-to-background ratios using a subset of well-characterized controls (e.g., doxorubicin for cytotoxicity, metformin for metabolic modulation).
   • Optimize compound dilution and dispensing protocols using DMSO-tolerant plate layouts to minimize false positives/negatives.
3. Screen Execution
   • Dispense compounds at desired concentrations (commonly 1–10 μM final) into assay wells using high-precision robotics.
   • Introduce target cells, biochemical substrates, or disease model systems as appropriate.
   • Run primary screens in single or duplicate; follow with confirmatory and dose-response rounds for hit validation.
4. Data Acquisition and Analysis
   • Apply automated plate readers or high-content imaging platforms for endpoint detection.
   • Leverage built-in positive/negative controls for normalization; utilize robust Z'-factor calculations (Z' > 0.5 as a quality benchmark).
   • Identify hits for further validation; cross-reference with public databases for mechanism, regulatory status, and known off-targets.
5. Secondary Profiling and Mechanistic Follow-up
   • Pursue pathway-specific assays (e.g., enzyme inhibitor screening, signal pathway regulation studies) and orthogonal validation (e.g., transcriptomics, proteomics).
   • Utilize the library's diversity to profile compound selectivity and polypharmacology across disease-relevant models.

Advanced Applications and Comparative Advantages

Facilitating Translational Breakthroughs: Case Studies and Data-Driven Insights

The DiscoveryProbe FDA-approved Drug Library has been pivotal in enabling rapid, mechanism-based discovery across diverse biomedical fields:

• Cancer Research Drug Screening: The library's inclusion of clinically validated kinase inhibitors, cytotoxins, and immune modulators enables high-throughput identification of candidate therapeutics and immune checkpoint regulators, as detailed in this analysis (complementing the library's focus on immune-oncology).
• Neurodegenerative Disease Drug Discovery: Compounds targeting neurotransmitter pathways, neuroinflammation, and synaptic function facilitate multi-parametric screening in neuron-based HCS assays, echoing approaches seen in this resource (which extends coverage to neurodegeneration and signal pathway regulation).
• Rare Disease Therapeutic Identification: Recent work by Terawaki et al. (iScience, 2025) exemplifies the library’s impact: using high-content screening of FDA-approved drugs, they identified triclabendazole as a suppressor of glycosaminoglycan accumulation in mucopolysaccharidosis-plus syndrome (MPSPS) models. This finding not only offers hope for MPSPS—an ultra-rare, previously untreatable disorder—but also demonstrates the library’s capacity for rapid drug repositioning and expansion into related lysosomal storage diseases.

Quantitatively, studies leveraging the DiscoveryProbe library report hit rates in the range of 0.5–2% for phenotypic screens, with confirmation rates exceeding 70% in secondary validation (see translational acceleration analysis). Automated workflows and robust compound annotation reduce false discovery and streamline the path from screening to lead optimization.

Comparative Edge in Drug Repositioning Screening

The DiscoveryProbe FDA-approved Drug Library stands apart by virtue of regulatory breadth, mechanistic diversity, and ready-to-use formulation. Unlike generic chemical collections, it directly supports translational applications—hits are by definition linked to established safety and pharmacokinetic data, expediting the transition from in vitro discovery to in vivo validation and clinical translation. This is further explored in this strategic roadmap, which contrasts the library’s translational utility with standard preclinical collections.

Troubleshooting and Optimization Tips: Maximizing Experimental Success

• Compound Precipitation or Insolubility: The pre-dissolved 10 mM DMSO format largely eliminates solubility issues. However, if precipitation is observed after thawing, gently vortex and briefly centrifuge plates. Avoid repeated freeze-thaw cycles.
• DMSO Toxicity: Maintain final DMSO concentrations below 0.5–1% in cell-based assays. Implement vehicle controls to monitor for DMSO-induced effects.
• Edge Effects and Evaporation: Utilize plate sealers and randomized plate layouts to mitigate positional artifacts. For long assays, humidified incubators are recommended.
• Hit Validation: Confirm initial hits with freshly diluted stocks and in dose-response format. Where possible, use orthogonal readouts (e.g., imaging plus biochemical endpoint) to rule out assay interference.
• Data Management: Leverage the included 2D barcodes and compound annotation to track provenance and batch-to-batch consistency. Integrate meta-data into LIMS or screening databases for future reproducibility and reanalysis.

Future Outlook: Expanding Horizons in Drug Discovery and Mechanistic Research

The DiscoveryProbe™ FDA-approved Drug Library is poised to remain at the forefront of translational research, enabling not only drug repositioning screening but also the systematic mapping of druggable pharmacological target space. As next-generation phenotypic assays (e.g., single-cell transcriptomics, CRISPR-based functional genomics) become routine, the synergy of curated, regulatory-approved compound libraries with high-content screening technologies will only deepen.

The success of recent studies—such as the identification of triclabendazole for MPSPS (Terawaki et al., 2025)—underscores the power of this approach. Ongoing integration of real-world clinical data, cheminformatics, and machine learning-driven hit triage will further accelerate the translation of bench discoveries into patient-ready therapies.

For researchers seeking to unlock the full potential of high-throughput screening, pharmacological target identification, and drug repositioning across cancer, neurodegeneration, and rare diseases, APExBIO’s DiscoveryProbe FDA-approved Drug Library offers a proven, scalable foundation. Explore the complete solution and technical details here.